Alison Elzayed
Business & Finance Writer | StockScope
Fluence Corporation Limited (ASX: FLC) has delivered stronger revenue and operating earnings during the first nine months of 2026, but a US$4.3 million quarterly cash outflow has exposed continuing pressure on its financial position.
The water treatment company's latest results show improving profitability alongside a declining order backlog and delayed customer payments.
With cash reserves falling to US$6.7 million, the critical question is whether Fluence can convert stronger operating performance into sustainable cash generation before liquidity becomes a greater concern.
Fluence's 29 October quarterly update confirmed continued improvement in its operating performance.
Revenue for the nine months to September reached approximately US$58 million, representing year-on-year growth of 11.3%.
EBITDA increased to US$4.7 million, already exceeding the US$4.1 million recorded for the full 2025 financial year.
Gross margins reached 35.2%, reflecting improved project execution and a greater contribution from higher-margin water treatment solutions.
However, the September quarter generated a US$4.3 million net operating cash outflow.
Cash reserves declined from US$10.9 million at 30 June to US$6.7 million at 30 September.
Management attributed much of the cash flow weakness to delayed customer payments totalling more than US$5.5 million, associated with Ivory Coast operations and maintenance fees and the Qurayyah water treatment project.
The company expects operating cash flow to return to positive territory during the December quarter.
However, that recovery depends on collecting outstanding payments and maintaining disciplined working capital management.
Fluence reported US$8 million in new orders during the September quarter, bringing year-to-date orders to US$31.6 million.
Its contracted backlog declined from US$59.8 million at 30 June to US$47.1 million at 30 September.
The approximately 21% reduction is significant because contracted orders provide visibility over future project revenue.
Management attributed weaker order intake partly to delays in customer investment decisions.
The company expects the December quarter to deliver its strongest order bookings of 2026.
Nevertheless, delayed opportunities are not equivalent to confirmed contracts.
Fluence must demonstrate that its commercial pipeline can replenish the order book while existing projects generate acceptable margins and timely customer receipts.
The latest Appendix 4C reported approximately US$20.3 million drawn against US$22.5 million in financing facilities.
This leaves approximately US$2.18 million in undrawn funding capacity.
The company's reported funding runway stood at 2.1 quarters, based on recent operating cash consumption and available liquidity.
This measure is sensitive to changes in customer receipts and does not represent a fixed deadline for additional financing.
Nevertheless, the relatively modest cash balance increases the importance of collecting overdue payments.
Although Fluence is generating stronger EBITDA, accounting profitability does not automatically translate into cash available for operations, debt servicing or investment.
Further delays in customer payments could increase working capital pressure and potentially require additional financing.
Fluence continues to expand its industrial water treatment activities across North America and Southeast Asia.
In May, the company secured a US$3.7 million contract to construct an industrial water treatment facility in Texas.
The facility is designed to process up to 1.5 million gallons of groundwater daily, with installation targeted for completion by the end of 2026.
Fluence also announced desalination contracts in Vietnam during July.
Its decentralised treatment systems provide solutions for industrial and municipal customers seeking wastewater treatment, water reuse and reduced dependence on large centralised infrastructure.
These technologies offer opportunities for equipment sales, operating contracts and recurring service revenue.
However, project delivery schedules, customer concentration and payment timing remain important commercial risks.
What stands out to us is the growing divergence between Fluence's improving operating profitability and its weakening cash position.
Nine-month EBITDA of US$4.7 million has already exceeded the company's full-year 2025 result, while gross margins of 35.2% suggest its shift towards higher-value treatment solutions is producing measurable benefits.
However, the September quarter's US$4.3 million operating cash outflow and decline in backlog to US$47.1 million demonstrate that earnings momentum has not yet translated into consistent cash generation.
We believe Fluence's established technology and international customer relationships provide a credible commercial foundation.
The market may be overlooking the immediate importance of collecting more than US$5.5 million in delayed payments, particularly given the limited undrawn financing capacity.
Our assessment would strengthen if Fluence delivered its anticipated December-quarter cash flow recovery, converted delayed opportunities into firm contracts and maintained improving margins without additional balance sheet pressure.
Fluence has demonstrated encouraging operational progress through higher revenue, improved gross margins and stronger EBITDA.
However, declining cash reserves, a smaller order backlog and substantial financing utilisation remain significant risks.
The December quarter represents the next important test of management's ability to convert outstanding customer payments into positive operating cash flow.
Investors should also monitor new order intake, backlog replenishment and completion of the Texas water treatment project.
For shareholders, improving operating profitability provides encouragement, but sustainable cash generation remains essential.
Fluence has demonstrated that its business model can produce stronger earnings. The decisive challenge is ensuring those earnings translate into reliable cash flow, improved liquidity and long-term financial resilience.
Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.
Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...
Mark Elzayed•
Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...
Danny Aad•
A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...
Alison Elzayed•
Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...
Alison Elzayed•
Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...
Alison Elzayed•
Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...
Danny Aad•